Avarieux
back to explore
SpyGlass Pharma, Inc. logo

SGP

SpyGlass Pharma, Inc.
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2026-02-06
$34.45
+0.81 (+2.41%)
last quote
Want the full multi-source brief on SGP?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
open in agent
Today
Open
$34.45
High
$35.15
Low
$34.08
Previous close
$33.64
Fundamentals
Market cap
$1.13B
P/E (TTM)
—
P/S (TTM)
—
P/B
—
Gross margin
—
Operating margin
—
Net margin
—
Rev growth (YoY)
—
EPS growth (YoY)
—
ROE
-56.78%
52W high
$33.96
52W low
$17.06
Beta
0.98x
Recent SEC filings
CIK 1778922filing-language history →
8-K2026-10-19
209 KB
8-K2026-10-01
215 KB
10-Q2026-08-06reports 2026-06-30
5,660 KB
8-K2026-08-06
288 KB
10-Q2026-05-14reports 2026-03-31
5,283 KB
8-K2026-05-14
242 KB
Recent news
2026-10-28 → 2026-11-04
Yahoo · 3d
SpyGlass Pharma (SGP) Reports Positive 4 Year Glaucoma Trial Results
SpyGlass Pharma (NasdaqGS:SGP) reported positive 4-year first in human trial data for its Bimatoprost Drug Pad IOL System in open angle glaucoma and ocular hypertension. The lead product showed sustained efficacy over four years in treated patients according to the newly released results. Investigators also reported a favorable safety profile across the 4 year follow up period for the implanted dr
SEC EDGAR Yahoo Finance TradingView Company website
This is the free preview

The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.

Start the trial